ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,863,613 | -51.9% | 350,963 | -13.7% | 0.00% | – |
| Q2 2023 | $3,874,469 | -78.3% | 406,555 | -74.9% | 0.00% | -100.0% |
| Q1 2023 | $17,839,514 | +404.3% | 1,621,774 | +578.5% | 0.00% | – |
| Q4 2022 | $3,537,761 | +22.4% | 239,038 | +58.0% | 0.00% | – |
| Q3 2022 | $2,891,000 | +254.3% | 151,257 | +295.0% | 0.00% | – |
| Q2 2022 | $816,000 | +322.8% | 38,295 | +283.0% | 0.00% | – |
| Q1 2022 | $193,000 | -23.1% | 10,000 | -17.4% | 0.00% | – |
| Q4 2021 | $251,000 | +60.9% | 12,110 | +86.0% | 0.00% | – |
| Q3 2021 | $156,000 | -12.4% | 6,510 | -0.4% | 0.00% | – |
| Q2 2021 | $178,000 | -85.5% | 6,533 | -84.6% | 0.00% | – |
| Q1 2021 | $1,225,000 | +768.8% | 42,361 | +746.4% | 0.00% | – |
| Q4 2020 | $141,000 | +6.8% | 5,005 | +10.8% | 0.00% | – |
| Q3 2020 | $132,000 | +15.8% | 4,519 | +19.7% | 0.00% | – |
| Q2 2020 | $114,000 | -18.0% | 3,776 | -19.2% | 0.00% | – |
| Q1 2020 | $139,000 | – | 4,672 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |